| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Riociguat |
| Brand | Adempas® |
| Indication | For the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH). |
| Assessment Process | |
| Rapid review commissioned | 11/04/2014 |
| Rapid review completed | 16/05/2014 |
| Rapid review outcome | Full HTA recommended at the current price. |
The HSE has approved reimbursement following confidential price negotiations.